Loading…

Developments in synthetic biology are altering the IP imperatives of biotechnology

While the accomplishments of the biotechnology industry have been substantial, recent technological advances promise to dramatically increase the power and utility of the discipline over the coming years. The term "synthetic biology" has been coined to describe the application of these pow...

Full description

Saved in:
Bibliographic Details
Published in:Vanderbilt journal of entertainment and technology law 2015-01, Vol.17 (2), p.385
Main Author: Holman, Christopher M
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 2
container_start_page 385
container_title Vanderbilt journal of entertainment and technology law
container_volume 17
creator Holman, Christopher M
description While the accomplishments of the biotechnology industry have been substantial, recent technological advances promise to dramatically increase the power and utility of the discipline over the coming years. The term "synthetic biology" has been coined to describe the application of these powerful new tools to the engineering of synthetic genetic sequences and organisms. In essence, synthetic biology represents the next iteration in the ongoing evolution of biotechnology, and hopes run high that in time, the fruits of synthetic biology will dwarf the past successes of conventional biotechnology. There is, however, some concern that the current patent-centric approach to Intellectual Property (IP), which has for years been the norm in biotechnology, is ill-suited for the needs of synthetic biologists and synthetic biology companies. This Article addresses these concerns and considers potential modifications to the IP system that might render it better suited to promote progress in synthetic biology. The Article begins with an overview of conventional biotechnology, including a discussion of the critical role IP has played in the growth and development of the conventional biotechnology industry. Next it describes the ongoing synthetic biology revolution, as illustrated by specific examples of various types of synthetic biology companies and user-innovators. The Article then explores the emerging IP imperatives of synthetic biology, highlighting numerous deficiencies under the current IP regime. It concludes with suggestions for adapting IP to the imperatives of synthetic biology, including a proposal to enlist copyright in the protection of synthetic biology innovations.
format article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A427758883</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A427758883</galeid><sourcerecordid>A427758883</sourcerecordid><originalsourceid>FETCH-LOGICAL-g1053-92d00d6ff679b4abb711ab20f921cbccd1bc72f47908a04a95775662ea56673b3</originalsourceid><addsrcrecordid>eNptzktrwzAMAGAfNljX7T8Yds6wHSeOj6V7FQobY4Pdiu3IqYdjl9gU-u_nPS6DIJBA-iR0hhZUcla1ovu4QJcpfRLCm6bmC_R6B0fw8TBCyAm7gNMp5D1kZ7B20cfhhNUEWPkMkwsDLjO8ecFuPMCksjtCwtF-0wxmH34WrtC5VT7B9V9doveH-7f1U7V9ftysV9tqoKSpK8l6QvrW2lZIzZXWglKlGbGSUaON6ak2glkuJOkU4Uo2QjRty0CVLGpdL9HN791Bedi5YGOelBldMrsVZwV3XVcXVc2oAUL538cA1pX2P38740v0MDozs_AFO4FqsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Developments in synthetic biology are altering the IP imperatives of biotechnology</title><source>Nexis UK</source><creator>Holman, Christopher M</creator><creatorcontrib>Holman, Christopher M</creatorcontrib><description>While the accomplishments of the biotechnology industry have been substantial, recent technological advances promise to dramatically increase the power and utility of the discipline over the coming years. The term "synthetic biology" has been coined to describe the application of these powerful new tools to the engineering of synthetic genetic sequences and organisms. In essence, synthetic biology represents the next iteration in the ongoing evolution of biotechnology, and hopes run high that in time, the fruits of synthetic biology will dwarf the past successes of conventional biotechnology. There is, however, some concern that the current patent-centric approach to Intellectual Property (IP), which has for years been the norm in biotechnology, is ill-suited for the needs of synthetic biologists and synthetic biology companies. This Article addresses these concerns and considers potential modifications to the IP system that might render it better suited to promote progress in synthetic biology. The Article begins with an overview of conventional biotechnology, including a discussion of the critical role IP has played in the growth and development of the conventional biotechnology industry. Next it describes the ongoing synthetic biology revolution, as illustrated by specific examples of various types of synthetic biology companies and user-innovators. The Article then explores the emerging IP imperatives of synthetic biology, highlighting numerous deficiencies under the current IP regime. It concludes with suggestions for adapting IP to the imperatives of synthetic biology, including a proposal to enlist copyright in the protection of synthetic biology innovations.</description><identifier>ISSN: 1942-678X</identifier><language>eng</language><publisher>Vanderbilt University, School of Law</publisher><subject>Analysis ; Biotechnology industries ; Influence ; Intellectual property ; Patentability ; Synthetic biology</subject><ispartof>Vanderbilt journal of entertainment and technology law, 2015-01, Vol.17 (2), p.385</ispartof><rights>COPYRIGHT 2015 Vanderbilt University, School of Law</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Holman, Christopher M</creatorcontrib><title>Developments in synthetic biology are altering the IP imperatives of biotechnology</title><title>Vanderbilt journal of entertainment and technology law</title><description>While the accomplishments of the biotechnology industry have been substantial, recent technological advances promise to dramatically increase the power and utility of the discipline over the coming years. The term "synthetic biology" has been coined to describe the application of these powerful new tools to the engineering of synthetic genetic sequences and organisms. In essence, synthetic biology represents the next iteration in the ongoing evolution of biotechnology, and hopes run high that in time, the fruits of synthetic biology will dwarf the past successes of conventional biotechnology. There is, however, some concern that the current patent-centric approach to Intellectual Property (IP), which has for years been the norm in biotechnology, is ill-suited for the needs of synthetic biologists and synthetic biology companies. This Article addresses these concerns and considers potential modifications to the IP system that might render it better suited to promote progress in synthetic biology. The Article begins with an overview of conventional biotechnology, including a discussion of the critical role IP has played in the growth and development of the conventional biotechnology industry. Next it describes the ongoing synthetic biology revolution, as illustrated by specific examples of various types of synthetic biology companies and user-innovators. The Article then explores the emerging IP imperatives of synthetic biology, highlighting numerous deficiencies under the current IP regime. It concludes with suggestions for adapting IP to the imperatives of synthetic biology, including a proposal to enlist copyright in the protection of synthetic biology innovations.</description><subject>Analysis</subject><subject>Biotechnology industries</subject><subject>Influence</subject><subject>Intellectual property</subject><subject>Patentability</subject><subject>Synthetic biology</subject><issn>1942-678X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNptzktrwzAMAGAfNljX7T8Yds6wHSeOj6V7FQobY4Pdiu3IqYdjl9gU-u_nPS6DIJBA-iR0hhZUcla1ovu4QJcpfRLCm6bmC_R6B0fw8TBCyAm7gNMp5D1kZ7B20cfhhNUEWPkMkwsDLjO8ecFuPMCksjtCwtF-0wxmH34WrtC5VT7B9V9doveH-7f1U7V9ftysV9tqoKSpK8l6QvrW2lZIzZXWglKlGbGSUaON6ak2glkuJOkU4Uo2QjRty0CVLGpdL9HN791Bedi5YGOelBldMrsVZwV3XVcXVc2oAUL538cA1pX2P38740v0MDozs_AFO4FqsQ</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Holman, Christopher M</creator><general>Vanderbilt University, School of Law</general><scope>ILT</scope></search><sort><creationdate>20150101</creationdate><title>Developments in synthetic biology are altering the IP imperatives of biotechnology</title><author>Holman, Christopher M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g1053-92d00d6ff679b4abb711ab20f921cbccd1bc72f47908a04a95775662ea56673b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Analysis</topic><topic>Biotechnology industries</topic><topic>Influence</topic><topic>Intellectual property</topic><topic>Patentability</topic><topic>Synthetic biology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holman, Christopher M</creatorcontrib><collection>LegalTrac</collection><jtitle>Vanderbilt journal of entertainment and technology law</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holman, Christopher M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Developments in synthetic biology are altering the IP imperatives of biotechnology</atitle><jtitle>Vanderbilt journal of entertainment and technology law</jtitle><date>2015-01-01</date><risdate>2015</risdate><volume>17</volume><issue>2</issue><spage>385</spage><pages>385-</pages><issn>1942-678X</issn><abstract>While the accomplishments of the biotechnology industry have been substantial, recent technological advances promise to dramatically increase the power and utility of the discipline over the coming years. The term "synthetic biology" has been coined to describe the application of these powerful new tools to the engineering of synthetic genetic sequences and organisms. In essence, synthetic biology represents the next iteration in the ongoing evolution of biotechnology, and hopes run high that in time, the fruits of synthetic biology will dwarf the past successes of conventional biotechnology. There is, however, some concern that the current patent-centric approach to Intellectual Property (IP), which has for years been the norm in biotechnology, is ill-suited for the needs of synthetic biologists and synthetic biology companies. This Article addresses these concerns and considers potential modifications to the IP system that might render it better suited to promote progress in synthetic biology. The Article begins with an overview of conventional biotechnology, including a discussion of the critical role IP has played in the growth and development of the conventional biotechnology industry. Next it describes the ongoing synthetic biology revolution, as illustrated by specific examples of various types of synthetic biology companies and user-innovators. The Article then explores the emerging IP imperatives of synthetic biology, highlighting numerous deficiencies under the current IP regime. It concludes with suggestions for adapting IP to the imperatives of synthetic biology, including a proposal to enlist copyright in the protection of synthetic biology innovations.</abstract><pub>Vanderbilt University, School of Law</pub></addata></record>
fulltext fulltext
identifier ISSN: 1942-678X
ispartof Vanderbilt journal of entertainment and technology law, 2015-01, Vol.17 (2), p.385
issn 1942-678X
language eng
recordid cdi_gale_infotracmisc_A427758883
source Nexis UK
subjects Analysis
Biotechnology industries
Influence
Intellectual property
Patentability
Synthetic biology
title Developments in synthetic biology are altering the IP imperatives of biotechnology
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T08%3A32%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Developments%20in%20synthetic%20biology%20are%20altering%20the%20IP%20imperatives%20of%20biotechnology&rft.jtitle=Vanderbilt%20journal%20of%20entertainment%20and%20technology%20law&rft.au=Holman,%20Christopher%20M&rft.date=2015-01-01&rft.volume=17&rft.issue=2&rft.spage=385&rft.pages=385-&rft.issn=1942-678X&rft_id=info:doi/&rft_dat=%3Cgale%3EA427758883%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g1053-92d00d6ff679b4abb711ab20f921cbccd1bc72f47908a04a95775662ea56673b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A427758883&rfr_iscdi=true